{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.8","value":"14.8"},{"groupId":"OG001","spread":"5.8","value":"13.5"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.7","value":"15.1"},{"groupId":"OG001","spread":"6.0","value":"15.9"}]}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.4","value":"15.3"},{"groupId":"OG001","spread":"5.6","value":"16.7"}]}],"title":"Week 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.0","value":"15.3"},{"groupId":"OG001","spread":"6.1","value":"16.0"}]}],"title":"Week 26/Early Withdrawal"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"description":"Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of cancer therapy thrombocytopenia (FACT-Th) questionnaire (six selected items). Scores could range from 0 (worst possible) to 24 (best possible).","dispersionType":"Standard Deviation","groups":[{"description":"Matching placebo tablets taken once a day","id":"OG000","title":"Placebo"},{"description":"Eltrombopag 50 mg oral tablets taken once a day (QD)","id":"OG001","title":"Eltrombopag 50 mg QD"}],"paramType":"MEAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Baseline, Week 6, Week 14, and Week 26/Early Withdrawal","title":"HR-QoL Instrument and Domain Scores for the FACT-Th Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment","type":"SECONDARY","unitOfMeasure":"Points on a scale (0-24)"}